ArticleCancers2020

Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390 Patients.

Ondrej Fiala et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.